| As you may be aware, members of the CRA recently identified a possible shortage of Erelzi® (biosimilar Etanercept) in some regions. Once identified, Dr. Carter Thorne of the CRA External Relations committee quickly worked with Sandoz to confirm, mitigate and help disseminate the proposed resolution for this shortage.
Sandoz has provided a communication to all prescribers providing details of the possible shortage and a solution to mitigate the impact to patients and providers. Please see Sandoz’s communication here.
The CRA Therapeutics committee have reviewed Sandoz’s proposed resolution and proposed strategy of considering a switch of impacted patients from Erelzi® to Sandoz’s second etanercept biosimilar, Rymti®, if clinically appropriate.
Please consult the Drug Shortages Canada website for the latest updates regarding Erelzi® supply as this situation evolves. We will continue to share updates as needed with all relevant stakeholders. In the meantime, if you have any questions, please contact Ahmad Zbib.
Sincerely, |
